I-Mab to Release 1H 2024 Financial Results on August 28, 2024
IMAB Stock | USD 1.07 0.03 2.73% |
About 62% of I Mab's investor base is looking to short. The analysis of the overall investor sentiment regarding I Mab suggests that many traders are alarmed. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
IMAB |
I-Mab , a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 800 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.
Read at finance.yahoo.com
I Mab Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
I Mab Fundamental Analysis
We analyze I Mab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of I Mab using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of I Mab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
I Mab is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
I Mab Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with I Mab stock to make a market-neutral strategy. Peer analysis of I Mab could also be used in its relative valuation, which is a method of valuing I Mab by comparing valuation metrics with similar companies.
Peers
I Mab Related Equities
DSGN | Design Therapeutics | 6.75 | ||||
AKRO | Akero Therapeutics | 4.71 | ||||
FHTX | Foghorn Therapeutics | 2.62 | ||||
KRYS | Krystal Biotech | 2.47 | ||||
STTK | Shattuck Labs | 1.83 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
RVMD | Revolution Medicines | 0.98 | ||||
KYMR | Kymera Therapeutics | 0.79 | ||||
IMVT | Immunovant | 0.25 | ||||
BPMC | Blueprint Medicines | 0.00 | ||||
GLUE | Monte Rosa | 0.00 | ||||
APLS | Apellis Pharmaceuticals | 0.00 | ||||
ERAS | Erasca | 0.54 | ||||
LYEL | Lyell Immunopharma | 0.69 | ||||
NRIX | Nurix Therapeutics | 1.80 | ||||
ASND | Ascendis Pharma | 2.65 |
Complementary Tools for IMAB Stock analysis
When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |